Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 6Recruiting 5Terminated 4Withdrawn 2Active not recruiting 2Unknown 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 4Prostatic Neoplasms, Castration-Resistant 2Neoplasms 2Neoplasm Metastasis 1Breast Neoplasms 1

Interventions

enzalutamide 2apalutamide 2Abiraterone Acetate 2radium Ra 223 dichloride 1abiraterone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Prostatic Neoplasms, Castration-Resistant × enzalutamide × Clear all
NCT05191017 2022-08-05

Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC

Nuvation Bio Inc.

Phase 1/2 Withdrawn
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT03325127 2018-10-31

Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study

Bayer

Withdrawn
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡